Genmab A/S and BioNovion struck a deal to evaluate several DuoBody product candidates targeting immune checkpoints. The companies announced that they have entered into a co-development and commercialization agreement to evaluate the product candidates. Genmab and BioNovion will contribute panels of antibodies for the creation of bispecific antibody products using …